Use of long-term antibiotic treatment in COPD patients in the UK: A retrospective cohort study

Primary Care Respiratory Journal

Volumn 22, Issue 3, 2013, Pages 271-277

  James, Gareth Dean Russell ^a,b   Petersen, Irene ^a   Nazareth, Irwin ^a   Wedzicha, Jadwiga A ^b   Donaldson, Gavin C ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibiotics; Cohort; COPD; Long term

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; DOXYCYCLINE; ERYTHROMYCIN; MOXIFLOXACIN; OXYTETRACYCLINE; PENICILLIN DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRESCRIPTION; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; COHORT STUDIES; DISEASE PROGRESSION; DOXYCYCLINE; ERYTHROMYCIN; FEMALE; GREAT BRITAIN; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXYTETRACYCLINE; PENICILLINS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84883314623     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2013.00061     Document Type: Article

References (37)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498-504. http://dx.doi.org/10.1016/S0140-6736(96)07492-2
2. Rabe KF, Wedzicha JA. Controversies in treatment of chronic obstructive pulmonary disease. Lancet 2011;378(9795):1038-47. http://dx.doi.org/10.1016/S0140-6736(11)61295-6
3. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. 2010. Available at: http://guidance.nice.org.uk/CG101/Guidance/pdf.
4. British Thoracic Society. Burden of lung disease report, 2nd edn. 2006. Available at: http://www.brit-thoracic.org.uk/Portals/0/Library/BTS%20Publications/burdeon_of_lung_disease2007.pdf
5. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60(11):925-31. http://dx.doi.org/10.1136/thx.2005.040527
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(5 Pt 1):1418-22. http://dx.doi.org/10.1164/ajrccm.157.5.9709032
7. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57(10):847-52. http://dx.doi.org/10.1136/thorax.57.10.847
8. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128-38. http://dx.doi.org/10.1056/NEJMoa0909883
9. Primary Care Respiratory Society. The management of exacerbations of chronic obstructive pulmonary disease in primary care. 2008. Available at: http://www.pcrs-uk.org/opinions/acuteexacerbations_final.pdf.
10. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370(9589):786-96. http://dx.doi.org/10.1016/S0140-6736(07)61382-8
11. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. Respir Res 2010;11:10. http://dx.doi.org/10.1186/1465-9921-11-10
12. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689-98. http://dx.doi.org/10.1056/NEJMoa1104623
13. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Longterm erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178(11):1139-47. http://dx.doi.org/10.1164/rccm.200801-145OC
14. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011). National Institutes of Health, National Heart, Lung and Blood Institute, 2011.
15. Lis Y, Mann RD. The VAMP research multi-purpose database in the U.K. J Clin Epidemiol 1995;48(3):431-43. http://dx.doi.org/10.1016/0895-4356(94)00137-F
16. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16(4):393-401. http://dx.doi.org/10.1002/pds.1335
17. Szatkowski L, Lewis S, McNeill A, Huang Y, Coleman T. Can data from primary care medical records be used to monitor national smoking prevalence? J Epidemiol Community Health 2012;66(9):791-5. http://dx.doi.org/10.1136/jech.2010.120154
18. Blak BT. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19(4):251.
19. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12(3):171-7.
20. Abstracts. Pharmacoepidemiol Drug Saf 2011;20(S1):S1-S364. http://dx.doi.org/10.1002/pds.2206
21. Petersen I, Gilbert R, Evans S, Ridolfi A, Nazareth I. Oral antibiotic prescribing during pregnancy in primary care: UK population-based study. J Antimicrob Chemother 2010;65(10):2238-46. http://dx.doi.org/10.1093/jac/dkq307
22. Infectious Disease Research Network. Available at: http://idrn.org/antimicrobial_prescribing/sdsddrug.htm, 2007.
23. Chisholm J. The Read clinical classification. BMJ 1990;300(6732):1092. http://dx.doi.org/10.1136/bmj.300.6732.1092
24. Townsend P. Health and deprivation: inequality and the North. 1988. Published in the UK by Croom Helm in association with Metheun, Inc.
25. Smith CJ, Gribbin J, Challen KB, Hubbard RB. The impact of the 2004 NICE guideline and 2003 General Medical Services contract on COPD in primary care in the UK. QJM 2008;101(2):145-53. http://dx.doi.org/10.1093/qjmed/hcm155
26. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137(5):1091-7. http://dx.doi.org/10.1378/chest.09-2029
27. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009;18(1):76-83. http://dx.doi.org/10.1002/pds.1688
28. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest 2001;120(3):730-3. http://dx.doi.org/10.1378/chest.120.3.730
29. Black P, Staykova T, Chacko E, Ram FS, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003(1):CD004105.
30. Andridge RR. A review of hot deck imputation for survey non-response. Int Stat Rev 2010;78(1):40. http://dx.doi.org/10.1111/j.1751-5823.2010.00103.x
31. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179(5):369-74. http://dx.doi.org/10.1164/rccm.200807-1067OC
32. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167(8):1090-5. http://dx.doi.org/10.1164/rccm.200210-1179OC
33. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57(9):759-64. http://dx.doi.org/10.1136/thorax.57.9.759
34. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55(2):114-20. http://dx.doi.org/10.1136/thorax.55.2.114
35. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J COPD 2008;3(3):331-50.
36. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004;59:540-1.
37. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170(4):400-07. http://dx.doi.org/10.1164/rccm.200305-648OC